|
Index | - | P/E | - | EPS (ttm) | -3.04 | Insider Own | 0.50% | Shs Outstand | 1.48M | Perf Week | -2.78% |
Market Cap | 254.92M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | - | Perf Month | 13.76% |
Income | -4.40M | PEG | - | EPS next Q | - | Inst Own | 0.20% | Short Float | - | Perf Quarter | 60.88% |
Sales | 5.80M | P/S | 43.95 | EPS this Y | -110.90% | Inst Trans | -70.04% | Short Ratio | 0.04 | Perf Half Y | 66.45% |
Book/sh | 0.58 | P/B | 13.26 | EPS next Y | - | ROA | -66.60% | Target Price | - | Perf Year | 217.77% |
Cash/sh | 0.02 | P/C | 318.65 | EPS next 5Y | - | ROE | -248.90% | 52W Range | 1.88 - 15.52 | Perf YTD | 71.65% |
Dividend | - | P/FCF | - | EPS past 5Y | 17.40% | ROI | -217.30% | 52W High | -50.45% | Beta | 0.58 |
Dividend % | - | Quick Ratio | 0.70 | Sales past 5Y | -25.00% | Gross Margin | 49.90% | 52W Low | 309.04% | ATR | 1.30 |
Employees | 22 | Current Ratio | 0.70 | Sales Q/Q | -76.90% | Oper. Margin | - | RSI (14) | 57.13 | Volatility | 20.21% 19.34% |
Optionable | No | Debt/Eq | 2.22 | EPS Q/Q | 122.50% | Profit Margin | -76.40% | Rel Volume | 0.32 | Prev Close | 7.94 |
Shortable | No | LT Debt/Eq | 0.56 | Earnings | - | Payout | - | Avg Volume | 1.86M | Price | 7.69 |
Recom | - | SMA20 | 36.38% | SMA50 | 5.57% | SMA200 | 50.42% | Volume | 588,733 | Change | -3.15% |
![]() | ||||||||||||||||||
![]() | ||||||||||||||||||
|
||||||||||||||||||
![]() | ||||||||||||||||||
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York. | ||||||||||||||||||
![]() | ||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite